Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Deepens Cooperation With PPD For Entire Biosimilar Portfolio

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. signed a memorandum of understanding with contract research organization Pharmaceutical Product Development Inc. to expand their ongoing cooperation in clinical trials to Celltrion's seven remaining biosimilars as well as its future biologic development projects
Advertisement

Related Content

Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017
Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017
Spurred By Demand For Global And Regional Trials In India, China And Japan, ICON Charts Asia Growth Strategy
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
Advertisement
UsernamePublicRestriction

Register

SC078012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel